Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Current Deferred Revenue (2023 - 2025)

Connect Biopharma Holdings' Current Deferred Revenue history spans 3 years, with the latest figure at $165000.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue changed N/A year-over-year to $165000.0; the TTM value through Sep 2025 reached $165000.0, changed N/A, while the annual FY2024 figure was $164000.0, 98.77% down from the prior year.
  • Current Deferred Revenue for Q3 2025 was $165000.0 at Connect Biopharma Holdings, up from $164000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $13.3 million in Q4 2023 and bottomed at $164000.0 in Q4 2024.
  • The 3-year median for Current Deferred Revenue is $164000.0 (2024), against an average of $2.8 million.
  • The largest YoY upside for Current Deferred Revenue was 98.77% in 2024 against a maximum downside of 98.77% in 2024.
  • A 3-year view of Current Deferred Revenue shows it stood at $13.3 million in 2023, then crashed by 98.77% to $164000.0 in 2024, then grew by 0.61% to $165000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Current Deferred Revenue are $165000.0 (Q3 2025), $164000.0 (Q2 2025), and $164000.0 (Q1 2025).